Try our beta test site
3 studies found for:    (lymphoma [CONDITION] OR CLL [CONDITION]) AND AEB071 [TREATMENT]
Show Display Options
Rank Status Study
1 Completed Safety and Efficacy of AEB071 and EVEROLIMUS in Patients With CD79-mutant or ABC Subtype Diffuse Large B-Cell Lymphoma
Condition: CD79 Mutant or ABC-subtype Diffuse Large B-Cell Lymphoma
Interventions: Drug: AEB071;   Drug: Everolimus
2 Terminated Study of AEB071 (a Protein Kinase C Inhibitor) in Patients With CD79-mutant Diffuse Large B-Cell Lymphoma
Condition: Diffuse Large B-Cell Lymphoma
Intervention: Drug: AEB071
3 Withdrawn Sotrastaurin Acetate in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia, Small Lymphocytic Leukemia, Prolymphocytic Leukemia, or Richter's Transformation
Conditions: Prolymphocytic Leukemia;   Recurrent Mantle Cell Lymphoma;   Recurrent Small Lymphocytic Lymphoma;   Refractory Chronic Lymphocytic Leukemia;   Richter Syndrome
Interventions: Drug: sotrastaurin acetate;   Other: pharmacological study;   Other: laboratory biomarker analysis

Study has passed its completion date and status has not been verified in more than two years.